From Name:
From Email:
To Name:
To Email:

Optional Message:


The impact of persistence with mirabegron usage versus switching to onabotulinumtoxinA on healthcare costs and resource utilization in patients with overactive bladder in the United States

from Journal of Medical Economics

To compare healthcare costs and resource utilization in patients with overactive bladder (OAB) in the United States who switch from mirabegron to onabotulinumtoxinA (onabotA) with those who persist on mirabegron. Materials and methods A retrospective observational claims analysis of the OptumHealth Administrative Claims database conducted between April 1, 2012 and September 30, 2015 used medical and pharmacy claims to identify patients with at least one OAB diagnosis who switched from mirabegron to onabotA (onabotA group) or persisted on mirabegron for at least 180 days (mirabegron persisters). more


Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063